Compare Charles River Laboratories Intl. Inc (CRL) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs LyondellBasell Industries NV — how do they compare? Charles River Laboratories Intl. Inc trades at $226.38 (market cap $11.14B), while LyondellBasell Industries NV trades at $57.57 (market cap $18.90B). The key difference: LyondellBasell Industries NV is the larger of the two by market cap, and LyondellBasell Industries NV pays a 7.04% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | LYB | |
|---|---|---|
Market Cap | $11.14B | $18.90B |
Sector | Health | Basic Materials |
52-Week High | $233.60 | $82.38 |
52-Week Low | $145.57 | $42.28 |
Enterprise Value | $14.00B | $30.52B |
Dividend Yield | — | 7.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
LyondellBasell (LYB) trades at $58.32, up 3.49% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported mixed earnings, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $50.5B in 2022 to $30.2B in 2025. Recent news highlights partnerships for sustainable packaging and upcoming Q2 2026 results. Despite negative net income margins and ROE, LYB maintains positive operating cash flow and a dividend payout.
LYB presents a cautious opportunity with analyst consensus leaning toward Buy (43.59%) and a $73.11 price target, suggesting 25% upside. Risks include persistent revenue declines, elevated debt, and industry headwinds, but cost-cutting and focus on high-margin polymers offer potential recovery. Investors should weigh the bullish technicals and analyst optimism against fundamental challenges in the chemical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
